Diagnostic Value of Glucose Transporter 1 (GLUT-1) Expression in Nested Variant of Urothelial Carcinoma
Yıl: 2019 Cilt: 35 Sayı: 1 Sayfa Aralığı: 22 - 27 Metin Dili: İngilizce DOI: 10.5146/tjpath.2018.01435 İndeks Tarihi: 06-05-2019
Diagnostic Value of Glucose Transporter 1 (GLUT-1) Expression in Nested Variant of Urothelial Carcinoma
Öz: Objective: Nested variant is bland-looking but aggressive subtype of urothelial carcinoma (UC). Cases having significant muscle invasion donot cause problems but small and superficial biopsies may be challenging due to morphological similarities between nested variant urothelialcarcinoma and benign urothelial lesions.Material and Method: We studied Glucose transporter 1 (GLUT-1), which is an integral membrane protein providing glucose pass throughplasma membrane down its concentration gradient, to see if it is useful for the differential diagnosis. Twenty five cases of nested variant urothelialcarcinoma and a control group consisting of 12 cases of cystitis glandularis, cystitis cystica and 4 cases of inverted papilloma were stained withGLUT-1 immunohistochemically. Membranous staining was scored on a scale of 0 to +3.Results: Eleven of 25 nested variant UC cases showed a score of 2 and 14 of them showed a score of 3 on immunostaining with GLUT-1. Twocases showed a score of 1 and 10 cases did not show any staining in the control group.Conclusion: Our results showed that GLUT-1 may be a helpful marker when morphological separation cannot be made between nested variantUC and benign urothelial leisons. We also think that anti-GLUT-1 antibody treatment may be an option in the targeted treatment of nestedvariant.
Anahtar Kelime: Konular:
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Moch H, Humphrey PA, Ulbright TM, Reuter VE. WHO Classification of Tumours of the Urinary System and Male Genital Organs. Lyon: International Agency for Research on Cancer, 2016.
- 2. Shanks JH, Iczkowski KA. Divergent differentiation in urothelial carcinoma and other bladder cancer subtypes with selected mimics. Histopathology. 2009;54: 885-900.
- 3. Tavora F, Epstein JI. Bladder cancer, pathological classification and staging. BJU Int. 2008;102:1216-20.
- 4. Holmäng S, Johansson SL. The nested variant of transitional cell carcinoma--a rare neoplasm with poor prognosis. Scand J Urol Nephrol. 2001;35:102-5.
- 5. Beltran AL, Cheng L, Montironi R, Blanca A, Leva M, Roupret M, Fonseca J, Vidal A, Menendez CL, Pallares J. Clinicopathological characteristics and outcome of nested carcinoma of the urinary bladder. Virchows Arch. 2014;465:199-205.
- 6. Volmar KE, Chan TY, De Marzo AM, Epstein JI. Florid von Brunn nests mimicking urothelial carcinoma: A morphologic and immunohistochemical comparison to the nested variant of urothelial carcinoma. Am J Surg Pathol. 2003;27: 1243-52.
- 7. Lin O, Cardillo M, Dalbagni G, Linkov I, Hutchinson B, Reuter VE. Nested variant of urothelial carcinoma: A clinicopathologic and immunohistochemical study of 12 cases. Mod Pathol. 2003;16: 1289-98.
- 8. Zhong M, Tian W, Zhuge J, Zheng X, Huang T, Cai D, Zhang D, Yang XJ, Argani P, Fallon JT, Epstein JI. Distinguishing nested variants of urothelial carcinoma from benign mimickers by TERT promoter mutation. Am J Surg Pathol. 2015;39: 127-31.
- 9. Wood IS, Trayhurn P. Glucose transporters (GLUT and SGLT): Expanded families of sugar transport proteins. Br J Nutr. 2003;89: 3-9.
- 10. Mueckler M, Thorens B. The SLC2 (GLUT) family of membrane transporters. Mol Aspects Med. 2013;34: 121-38.
- 11. Erdamar H, Hacıevliyagil Kazancı F, Gök S. Biochemical changes in cancer. J Clin Anal Med. 2014;5 Suppl 3: 430-8.
- 12. Szablewski L. Expression of glucose transporters in cancers. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 2013;1835: 164-9.
- 13. Brown RS, Wahl RL. Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer. 1993;72:2979-85.
- 14. Younes M, Brown RW, Stephenson M, Gondo M, Cagle PT. Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer. 1997;80: 1046-51.
- 15. AJCC cancer staging manual. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds). 7th ed. New York, NY: Springer, 2010.
- 16. Kato Y, Tsuta K, Seki K, Maeshima AM, Watanabe S, Suzuki K, Asamura H, Tsuchiya R, Matsuno Y. Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma. Mod Pathol.2007;20: 215-20.
- 17. Weiner MF, Miranda RN, Bardales RH, Mukunyadzi P, Baker SJ, Korourian S, De Las Casas LE. Diagnostic value of GLUT-1 immunoreactivity to distinguish benign from malignant cystic squamous lesions of the head and neck in fine-needle aspiration biopsy material. Diagn Cytopathol. 2004;31: 294-9.
- 18. Lee JH, Kim YW, Chang SG. Glucose transporter-1 expression in urothelial papilloma of the bladder. Urol Int. 2005;74: 268-71.
- 19. Chang S, Lee S, Lee C, Kim JI, Kim Y. Expression of the human erythrocyte glucose transporter in transitional cell carcinoma of the bladder. Urology. 2000;55(3): 448-52.
- 20. Reis H, Tschirdewahn S, Szarvas T, Rübben H, Schmid KW, Grabellus F. Expression of GLUT1 is associated with increasing grade of malignancy in non-invasive and invasive urothelial carcinomas of the bladder. Oncol Lett. 2011;2: 1149-53.
- 21. Hussein YR, Bandyopadhyay S, Semaan A, Ahmed Q, Albashiti B, Jazaerly T, Nahleh Z, Ali-Fehmi R. Glut-1 expression correlates with basal-like breast cancer. Transl Oncol. 2011;4: 321-7.
- 22. Evans A, Bates V, Troy H, Hewitt S, Holbeck S, Chung YL, Philips R, Stubbs M, Griffiths J, Airley R. Glut-1 as a therapeutic target: Increased chemoresistance and HIF-1-independent link with cell turnover is revealed through COMPARE analysis and metabolomic studies. Cancer Chemother Pharmacol. 2008;61: 377-93.
- 23. Pujol-Gimenez J, de Heredia FP, Idoate MA, Airley R, Pilar Lostao M, Ewans AR. Could GLUT12 be a potential therapeutic target in cancer treatment? A Preliminary Report J Cancer. 2015;6: 139-43.
- 24. Chen CP, Li X, Zhang LR, Min JM, Chan JYW, Fung KP, Wang SQ, Zhang LH. Synthesis of antisense oligonucleotide-peptide conjugate targeting to GLUT-1 in HepG-2 and MCF-7 cells. Bioconjug Chem. 2002;13: 525-9.
- 25. Rastogi S, Banerjee S, Chellappan S, Simon GR. Glut-1 antibodies induce growth arrest and apoptosis in human cancer cell lines. Cancer Lett. 2007;257:244-51.
- 26. Liu Y, Cao Y, Zhang W, Bergemier S, Qian Y, Akbar H, Colvin R, Ding J, Tong L, Wu S, Hines J, Chen X. A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo. Mol Cancer Ther. 2012;11:1672-82.
- 27. Linder BJ, Frank I, Cheville JC, Thompson RH, Thapa P, Tarrell RF, Boorjian SA. Outcomes following radical cystectomy for nested variant of urothelial carcinoma: A matched cohort analysis. J Urol. 2013;189:1670-5.
- 28. Younes M, Juarez D, Lechago LV, Lerner SP. Glut 1 expression in transitional cell carcinoma of the urinary bladder is associated with poor patient survival. Anticancer Res. 2001;21:575-8.
| APA | BOYACİ C, BEHZATOĞLU K (2019). Diagnostic Value of Glucose Transporter 1 (GLUT-1) Expression in Nested Variant of Urothelial Carcinoma. , 22 - 27. 10.5146/tjpath.2018.01435 |
| Chicago | BOYACİ Ceren,BEHZATOĞLU Kemal Diagnostic Value of Glucose Transporter 1 (GLUT-1) Expression in Nested Variant of Urothelial Carcinoma. (2019): 22 - 27. 10.5146/tjpath.2018.01435 |
| MLA | BOYACİ Ceren,BEHZATOĞLU Kemal Diagnostic Value of Glucose Transporter 1 (GLUT-1) Expression in Nested Variant of Urothelial Carcinoma. , 2019, ss.22 - 27. 10.5146/tjpath.2018.01435 |
| AMA | BOYACİ C,BEHZATOĞLU K Diagnostic Value of Glucose Transporter 1 (GLUT-1) Expression in Nested Variant of Urothelial Carcinoma. . 2019; 22 - 27. 10.5146/tjpath.2018.01435 |
| Vancouver | BOYACİ C,BEHZATOĞLU K Diagnostic Value of Glucose Transporter 1 (GLUT-1) Expression in Nested Variant of Urothelial Carcinoma. . 2019; 22 - 27. 10.5146/tjpath.2018.01435 |
| IEEE | BOYACİ C,BEHZATOĞLU K "Diagnostic Value of Glucose Transporter 1 (GLUT-1) Expression in Nested Variant of Urothelial Carcinoma." , ss.22 - 27, 2019. 10.5146/tjpath.2018.01435 |
| ISNAD | BOYACİ, Ceren - BEHZATOĞLU, Kemal. "Diagnostic Value of Glucose Transporter 1 (GLUT-1) Expression in Nested Variant of Urothelial Carcinoma". (2019), 22-27. https://doi.org/10.5146/tjpath.2018.01435 |
| APA | BOYACİ C, BEHZATOĞLU K (2019). Diagnostic Value of Glucose Transporter 1 (GLUT-1) Expression in Nested Variant of Urothelial Carcinoma. Türk Patoloji Dergisi, 35(1), 22 - 27. 10.5146/tjpath.2018.01435 |
| Chicago | BOYACİ Ceren,BEHZATOĞLU Kemal Diagnostic Value of Glucose Transporter 1 (GLUT-1) Expression in Nested Variant of Urothelial Carcinoma. Türk Patoloji Dergisi 35, no.1 (2019): 22 - 27. 10.5146/tjpath.2018.01435 |
| MLA | BOYACİ Ceren,BEHZATOĞLU Kemal Diagnostic Value of Glucose Transporter 1 (GLUT-1) Expression in Nested Variant of Urothelial Carcinoma. Türk Patoloji Dergisi, vol.35, no.1, 2019, ss.22 - 27. 10.5146/tjpath.2018.01435 |
| AMA | BOYACİ C,BEHZATOĞLU K Diagnostic Value of Glucose Transporter 1 (GLUT-1) Expression in Nested Variant of Urothelial Carcinoma. Türk Patoloji Dergisi. 2019; 35(1): 22 - 27. 10.5146/tjpath.2018.01435 |
| Vancouver | BOYACİ C,BEHZATOĞLU K Diagnostic Value of Glucose Transporter 1 (GLUT-1) Expression in Nested Variant of Urothelial Carcinoma. Türk Patoloji Dergisi. 2019; 35(1): 22 - 27. 10.5146/tjpath.2018.01435 |
| IEEE | BOYACİ C,BEHZATOĞLU K "Diagnostic Value of Glucose Transporter 1 (GLUT-1) Expression in Nested Variant of Urothelial Carcinoma." Türk Patoloji Dergisi, 35, ss.22 - 27, 2019. 10.5146/tjpath.2018.01435 |
| ISNAD | BOYACİ, Ceren - BEHZATOĞLU, Kemal. "Diagnostic Value of Glucose Transporter 1 (GLUT-1) Expression in Nested Variant of Urothelial Carcinoma". Türk Patoloji Dergisi 35/1 (2019), 22-27. https://doi.org/10.5146/tjpath.2018.01435 |
